Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 0.64 |
| ▸ | DPP8 | Q6V1X1 | 10/20 | 0.63 |
| ▸ | DPP7 | Q9UHL4 | 4/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.52 |
| ▸ | ACE | P12821 | 1/20 | 0.52 |
| ▸ | HTR2A | P28223 | 1/20 | 0.52 |
| ▸ | FAP | Q12884 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8029326 | 0.91 | DPP4 (0.62) | DPP4DPP8DPP7CYP3A4DPP9 | |
| SCHEMBL8017858 | 0.90 | DPP4 (0.66) | DPP4DPP8DPP7DPP9ACE | |
| SCHEMBL788194 | 0.90 | DPP4 (0.63) | DPP4DPP8DPP7CYP3A4DPP9 | |
| SCHEMBL8027561 | 0.88 | DPP4 (0.61) | DPP4DPP8DPP7DPP9ACE | |
| SCHEMBL3777544 | 0.85 | DPP4 (0.55) | DPP4DPP8DPP7CYP3A4DPP9 | |
| SCHEMBL3772444 | 0.85 | DPP4 (0.55) | DPP4DPP8DPP7CYP3A4DPP9 | |
| SCHEMBL4399771 | 0.84 | DPP4 (0.67) | DPP4DPP8DPP7CYP3A4DPP9 | |
| SCHEMBL8033086 | 0.83 | DPP4 (0.52) | DPP4DPP8DPP7CYP3A4DPP9 | |
| SCHEMBL13002372 | 0.82 | DPP4 (0.55) | DPP4DPP8DPP7CYP3A4DPP9 | |
| SCHEMBL8028184 | 0.81 | DPP4 (0.57) | DPP4DPP8DPP7CYP3A4DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2250157-B1 | NOVEL HETEROCYCLIC COMPOUNDS | PANACEA BIOTEC LTD (IN) | 2014-11-05 | — | — | EP | disclosed |
| US-8455479-B2 | Heterocyclic compounds | PANACEA BIOTEC LIMITED (IN) | 2013-06-04 | — | — | US | disclosed |
| US-8455479-B2 | Heterocyclic compounds | PANACEA BIOTEC LIMITED (IN) | 2013-06-04 | — | — | US | disclosed |
| US-20100311732-A1 | NOVEL HETEROCYCLIC COMPOUNDS | PANACEA BIOTEC PHARMA LIMITED (IN) | 2010-12-09 | — | — | US | disclosed |
| US-20100311732-A1 | NOVEL HETEROCYCLIC COMPOUNDS | PANACEA BIOTEC PHARMA LIMITED (IN) | 2010-12-09 | — | — | US | disclosed |
| WO-2009093269-A1 | NOVEL HETEROCYCLIC COMPOUNDS | PANACEA BIOTEC LIMITED (IN) | 2009-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311732-A1 | NOVEL HETEROCYCLIC COMPOUNDS | DPP4, DPP3, DPP8 | DPP4 1/4885DPP8 3/4885DPP7 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.